Royal Naval Patrol Service

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Supplies, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Science, Culture, Broad Institute, Cell, Massachusetts General Hospital, Partner (business rank), Environment, Trust, RNP, MIT, Spark Therapeutics, Patient, Harvard University, Nature Biotechnology, Tissue, Head, Protein, Therapy, Former, Safety, Royal Naval Patrol Service, FDA, Management

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.
  • The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.
  • “The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.
  • In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

NPS Prism reveals America's customer loyalty leaders in its latest U.S. Benchmark Report

Retrieved on: 
Wednesday, February 21, 2024
Pharmacy, BNPL, Telecommunications, NPS, Public utility, DIY, Communication, Sherwin-Williams, Mint Mobile, Nuclear power plant, Royal Naval Patrol Service, Bain & Company, Interview, CX, Retail

NEW YORK, Feb. 21, 2024 /PRNewswire/ -- NPS Prism®, Bain & Company's customer experience (CX) benchmarking service, reveals America's customer loyalty leaders in its latest U.S. Benchmarks Report, The research measures Net Promoter ScoreSM, a widely used metric of customer sentiment and loyalty, using a double-blind survey of thousands of customers to assess more than 1,000 companies across 10 industries. The result is the most comprehensive, unbiased customer loyalty leaderboard available on the market. The companies below received the highest rankings in their sectors.

Key Points: 
  • Payment solutions like peer-to-peer (P2P) and buy now, pay later (BNPL) have continued to see increased usage since 2021 and, with that, higher customer expectations.
  • The impact of inflation and pricing on utility customer sentiment depends on critical factors, such as proactive communication and consistent transparency relating to rate changes.
  • In a competitive pharmacy landscape, local independent pharmacies and Publix emerge as industry leaders as they shift focus to personalized customer experience.
  • This report summarizes each industry's key customer sentiment metrics, including relationship NPS (rNPS), which captures the overall customer sentiment about a particular brand, and/or product NPS (pNPS), which measures customer satisfaction at the product level.

Future Fields and Jenthera Therapeutics Collaborate to Develop Novel Protein for the Delivery of Cancer Biologics

Retrieved on: 
Tuesday, June 13, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, GMP, Royal Naval Patrol Service, CRISPR, Nanoparticle, Partnership, Therapy, Gene editing, Lipid, Research, Fruit, Carbon, Doctor of Philosophy, Bioreactor, Incidence, Patient, Philip Roche, A-DNA, Virus, Synthetic biology, Safety, Fine chemical, Vaccine

The Future Fields platform, the EntoEngine™, will be used to mass-produce this novel protein under development more sustainably and cost-effectively than conventional approaches to biopharmaceutical production techniques.

Key Points: 
  • The Future Fields platform, the EntoEngine™, will be used to mass-produce this novel protein under development more sustainably and cost-effectively than conventional approaches to biopharmaceutical production techniques.
  • Future Fields is actively engaging with big and small biotech companies alike to form research collaborations for strategic proteins of interest.
  • Following sustainable production with the EntoEngine™, Jenthera can deliver tailored gene editing complexes that selectively target the genomes of cancer cells, delivering in vivo anti-cancer therapeutics.
  • Future Fields aims to help the biopharmaceutical industry reduce the carbon impact caused by traditional bioreactors and enhance sustainability through synthetic biology.

SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process

Retrieved on: 
Wednesday, May 18, 2022
Oncology, Health, Stem Cells, Genetics, Clinical Trials, Biotechnology, Regenerative medicine, Phenotype, RNA transfection, Health, Stem cell, Population, Autoimmunity, Private Securities Litigation Reform Act, Microarray, POC, TAC, U.S. Securities and Exchange Commission, HSC, Degenerative disease, HPV16, Patient, Infection, Immune tolerance, Stemcell Technologies, RUO, Monocyte, Society, COVID-19, B2M, Research, Gene, CFC, Electroporation, TCR, Coeliac disease, AAC, NK, Time, Toxicity, CRISPR, CCR5, American Society of Gene and Cell Therapy, Risk, Royal Naval Patrol Service, Therapy, Confidentiality, Cell, Cancer, NYSE, Annual report, SQZ, Vaccine, Pharmaceutical industry, Fine chemical

SQZ Biotechnologies (NYSE: SQZ) announced today that the companys first generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development.

Key Points: 
  • SQZ Biotechnologies (NYSE: SQZ) announced today that the companys first generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development.
  • Our current clinical manufacturing process is under 24 hours - comparatively faster than other cell therapy manufacturing approaches.
  • We look forward to its planned first clinical use in our red blood cell derived SQZ TAC program for celiac disease.
  • The SQZ POC manufacturing system integrates and automates, among other things, cell isolation, cell washing, Cell Squeeze intracellular delivery technology, and product filling.

Bain & Company Launches NPS Prism For Grocery

Retrieved on: 
Wednesday, October 6, 2021
Prism, Bain & Company, Insurance, Warehouse, Grocery store, Interview, Worshipful Company of Grocers, PTS, Royal Naval Patrol Service, COVID-19, Amazon, Benchmarking, Environment, Social justice, Gaps, Company, Costco, Aldi, Gold, Channel, Learning, Organization, Economic development, Ecosystem, Net, NPS, Industry, Education, Retail, Marketing

NEW YORK, Oct. 6, 2021 /PRNewswire/ --Bain & Company today announces the launch of the NPS Prism tailored for US grocers.

Key Points: 
  • NEW YORK, Oct. 6, 2021 /PRNewswire/ --Bain & Company today announces the launch of the NPS Prism tailored for US grocers.
  • NPS Prism for grocers helps identify who is leading in each sub-segment of market.
  • "Grocery has been one of the sectors most affected by the Covid-19 pandemic," said Jason Barro , a Bain & Company partner and founder of NPS Prism.
  • NPS Prism for Grocery joins the growing suite of NPS Prism services tailored to specific industries including banking, insurance, utilities, telecom, auto and airlines.